Umecrine Cognition announces positive top-line Phase 1 data with GR3027

Umecrine Cognition announces positive top-line Phase 1 data with GR3027 in hepatic encephalopathy demonstrating safety, tolerability and CNS target engagement

STOCKHOLM/UMEÅ – November 3, 2016. Umecrine Cognition AB, a Karolinska Development (Nasdaq Stockholm: KDEV) portfolio company today announced positive top-line results from its Phase 1 first in human clinical trial with GR3027, a novel orally active GABAA receptor modulating steroid antagonist, in development for treatment of hepatic encephalopathy (HE) in patients with liver cirrhosis. “We are very encouraged by the pharmacodynamic effect of GR3027 in our Phase 1 trials, along with its favorable safety and tolerability profile,” said Magnus Doverskog, CEO of Umecrine Cognition. “These findings show that oral GR3027 reaches the brain target with an expected mechanism of action and combined with our previous pre-clinical results [1] support our belief that GR3027 could be an attractive new therapy for patients with liver cirrhosis and hepatic encephalopathy.”

 For more information, please visit www.umecrinecognition.com